"The acquisition of Seppro significantly strengthens Sigma-Aldrich's position in antibody-based depletion technology," said Dr. Dave Smoller, President of Sigma-Aldrich's Research Biotech Business Unit. "Our goal, through acquisitions and collaborations, is to provide researchers with the most comprehensive and highly characterized portfolio of antibodies and antibody products."
Seppro technology joins Sigma-Aldrich's leading collection of depletion products, including ProteoPrep(R) kits for the removal of highly abundant proteins, such as albumin and IgG, from human serum and plasma. For more information on Seppro, and all Sigma-Aldrich proteomics sample preparation products, visit http://www.sigma-aldrich.com/genway.
About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Its biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing. The Company has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 36 countries and has 8,000 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating Customer Success through innovation and Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit its award-winning Web site at http://www.sigma-aldrich.com.
About GenWay Biotech: Genway Biotech Inc. is a
Copyright©2009 PR Newswire.
All rights reserved